expert roundtables by David A. Hafler, MD, Staley Brod, MD, Dean Wingerchuk, MD, FRCP(C)
Highly effective anti-inflammatory therapies are available for treating patients with relapsing-remitting multiple sclerosis (MS). The disease star......READ MORE
expert roundtables by David A. Hafler, MD, Staley Brod, MD, Dean Wingerchuk, MD, FRCP(C)
Many adults with multiple sclerosis (MS) are no longer able to work as early as 5 years after diagnosis, and this is most commonly because of disab......READ MORE
expert roundtables by David A. Hafler, MD, Staley Brod, MD, Dean Wingerchuk, MD, FRCP(C)
Neurodegeneration occurs in all stages of multiple sclerosis (MS), but neurological disability is variable among individual patients. Demyelination......READ MORE
expert roundtables by David A. Hafler, MD, Staley Brod, MD, Dean Wingerchuk, MD, FRCP(C)
Concordance, compared with compliance and adherence, involves patients having an active role in treatment decisions. One aim of the concordance mod......READ MORE
expert roundtables by David A. Hafler, MD, Staley Brod, MD, Dean Wingerchuk, MD, FRCP(C)
Disease-modifying drugs (DMDs) are indicated to reduce relapse rates and slow disease progression in patients with relapsing-remitting multiple scl......READ MORE
clinical topic updates by Dean Wingerchuk, MD, FRCP(C)
The neuropsychological aspects of multiple sclerosis (MS), including cognitive dysfunction, are some of the most disabling symptoms of the disease,......READ MORE
